Hangzhou Tigermed Consulting Co., Ltd. (HNGZY)
USD 4.14
(0.0%)
USD 4.14
(0.0%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 3.29 Million USD | 3.29% |
| 2022 | 3.19 Million USD | 233.99% |
| 2021 | 956.32 Thousand USD | 32.48% |
| 2020 | 721.88 Thousand USD | 316.95% |
| 2019 | 173.13 Thousand USD | -66.63% |
| 2018 | 518.89 Thousand CNY | 3598.71% |
| 2017 | 14.02 Thousand CNY | -76.57% |
| 2016 | 59.87 Thousand CNY | -86.31% |
| 2015 | 437.25 Thousand CNY | 48.0% |
| 2014 | 295.45 Thousand CNY | -16.85% |
| 2013 | 355.3 Thousand CNY | 32.22% |
| 2012 | 268.72 Thousand CNY | 182.07% |
| 2011 | 95.26 Thousand CNY | 118.6% |
| 2010 | 43.58 Thousand CNY | 0.0% |
| 2009 | - CNY | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 23.67 Million CNY | 302.82% |
| 2024 Q3 | 22.19 Million CNY | 0.27% |
| 2024 Q2 | 22.13 Million CNY | -76.51% |
| 2023 Q4 | 23.39 Million CNY | -14.1% |
| 2023 Q3 | 27.23 Million CNY | 2.65% |
| 2023 FY | 3.29 Million USD | 3.29% |
| 2023 Q1 | 3.36 Million USD | 5.36% |
| 2023 Q2 | 26.53 Million CNY | 688.45% |
| 2022 Q3 | 4.94 Million USD | -70.83% |
| 2022 Q4 | 3.19 Million USD | -35.46% |
| 2022 FY | 3.19 Million USD | 233.99% |
| 2022 Q1 | 7.64 Million CNY | 25.38% |
| 2022 Q2 | 16.96 Million CNY | 121.99% |
| 2021 Q4 | 6.09 Million CNY | 3.53% |
| 2021 FY | 956.32 Thousand USD | 32.48% |
| 2021 Q1 | 802.83 Thousand CNY | -83.0% |
| 2021 Q2 | 855.1 Thousand CNY | 6.51% |
| 2021 Q3 | 5.88 Million CNY | 588.51% |
| 2020 Q2 | 1.29 Million CNY | -46.26% |
| 2020 Q3 | 1.55 Million CNY | 19.77% |
| 2020 Q4 | 4.72 Million CNY | 204.06% |
| 2020 FY | 721.88 Thousand USD | 316.95% |
| 2020 Q1 | 2.41 Million CNY | 100.11% |
| 2019 Q3 | 689.34 Thousand CNY | 10.09% |
| 2019 Q2 | 626.18 Thousand CNY | 7.8% |
| 2019 Q4 | 1.2 Million CNY | 74.89% |
| 2019 Q1 | 580.89 Thousand CNY | 11.95% |
| 2019 FY | 173.13 Thousand USD | -66.63% |
| 2018 Q1 | 17.6 Thousand CNY | 25.5% |
| 2018 Q3 | 343.39 Thousand CNY | -68.76% |
| 2018 Q2 | 1.09 Million CNY | 6143.74% |
| 2018 Q4 | 518.89 Thousand CNY | 51.11% |
| 2018 FY | 518.89 Thousand CNY | 3598.71% |
| 2017 Q3 | 61.82 Thousand CNY | -13.86% |
| 2017 Q1 | 65.98 Thousand CNY | 10.19% |
| 2017 FY | 14.02 Thousand CNY | -76.57% |
| 2017 Q4 | 14.02 Thousand CNY | -77.31% |
| 2017 Q2 | 71.77 Thousand CNY | 8.79% |
| 2016 Q3 | 324.17 Thousand CNY | -4.34% |
| 2016 FY | 59.87 Thousand CNY | -86.31% |
| 2016 Q4 | 59.87 Thousand CNY | -81.53% |
| 2016 Q2 | 338.87 Thousand CNY | -58.16% |
| 2016 Q1 | 810.01 Thousand CNY | 85.25% |
| 2015 FY | 437.25 Thousand CNY | 48.0% |
| 2015 Q3 | 488.44 Thousand CNY | 79.73% |
| 2015 Q4 | 437.25 Thousand CNY | -10.48% |
| 2015 Q2 | 271.77 Thousand CNY | -59.32% |
| 2015 Q1 | 668.13 Thousand CNY | 126.14% |
| 2014 Q2 | 423.67 Thousand CNY | 89.67% |
| 2014 FY | 295.45 Thousand CNY | -16.85% |
| 2014 Q1 | 223.36 Thousand CNY | -37.13% |
| 2014 Q4 | 295.45 Thousand CNY | 23.13% |
| 2014 Q3 | 239.95 Thousand CNY | -43.36% |
| 2013 Q3 | 113.03 Thousand CNY | -4.55% |
| 2013 Q4 | 355.3 Thousand CNY | 214.33% |
| 2013 FY | 355.3 Thousand CNY | 32.22% |
| 2013 Q1 | 139.94 Thousand CNY | -47.92% |
| 2013 Q2 | 118.42 Thousand CNY | -15.38% |
| 2012 Q3 | 242.39 Thousand CNY | 156.91% |
| 2012 FY | 268.72 Thousand CNY | 182.07% |
| 2012 Q2 | 94.35 Thousand CNY | 0.0% |
| 2012 Q4 | 268.72 Thousand CNY | 10.86% |
| 2011 Q4 | 95.26 Thousand CNY | 0.0% |
| 2011 FY | 95.26 Thousand CNY | 118.6% |
| 2010 FY | 43.58 Thousand CNY | 0.0% |
| 2009 FY | - CNY | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| American Bio Medica Corporation | 379 Thousand USD | -770.478% |
| Arrayit Corporation | 464.19 Thousand USD | -610.721% |
| Atlantic International Corp. | - USD | -Infinity% |
| Biocept, Inc. | 757 Thousand USD | -335.814% |
| Bioqual, Inc. | - USD | -Infinity% |
| CardioGenics Holdings Inc | -2385.00 USD | 138427.505% |
| DermTech, Inc. | 1 Million USD | -228.597% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| HTG Molecular Diagnostics, Inc. | 909.32 Thousand USD | -262.808% |
| iMD Companies, Inc. | 38.31 Thousand USD | -8510.27% |
| IDenta Corp. | 442.28 Thousand USD | -645.931% |
| Interpace Biosciences, Inc. | 1.22 Million USD | -168.876% |
| Integrative Health Technologies, Inc. | - USD | -Infinity% |
| InVitro International | 163.13 Thousand USD | -1922.32% |
| Lumos Diagnostics Holdings Limited | 784 Thousand USD | -320.805% |
| Many Bright Ideas Technologies Inc. | -375.00 USD | 879862.933% |
| Medical Imaging Corp. | - USD | -Infinity% |
| NovelStem International Corp. | - USD | -Infinity% |
| Optigenex Inc. | 468.77 Thousand USD | -603.774% |
| PharmChem, Inc. | 391.93 Thousand USD | -741.745% |
| Proteome Sciences plc | 1.06 Million USD | -209.63% |
| Response Genetics, Inc | 133 Thousand USD | -2380.535% |
| Rennova Health, Inc. | 242.64 Thousand USD | -1259.645% |
| RushNet, Inc. | - USD | -Infinity% |
| ScreenPro Security Inc. | 73.89 Thousand USD | -4364.472% |
| Stella Diagnostics Inc. | - USD | -Infinity% |
| StageZero Life Sciences Ltd. | 95.62 Thousand USD | -3350.195% |
| Todos Medical Ltd. | 1.02 Million USD | -223.126% |